Shanghai InnoStar Bio-tech Co., Ltd. (SHA:688710)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Medical Labs & Research	1.14B	1.04B	863.07M	-
Medical Labs & Research Growth	9.94%	20.32%	-	-
Total	1.14B	1.04B	863.07M	-
Total Growth	9.94%	20.32%	-	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Overseas	15.20M	-
South China	39.33M	-
North China	85.91M	-
Southwest	44.59M	-
Central China	3.06M	-
Northwest	5.22M	-
Northeast	23.49M	-
East China	645.42M	-
Total	862.21M	-

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 16, 2026

Data Sources Report a data error